Estimating the exact pneumococcal disease burden in India continues to be challenging, while morbidity and mortality rates remain high. Vaccination to prevent invasive pneumococcal infections has not yet been introduced in the universal Immunization programme (uIp), even as paediatricians advocate its use. Studies on serotype prevalence are still relevant in the Indian context. Some multicentric and single centre studies on serotypes involved in invasive pneumococcal disease (IpD) have been published 1, 2 . unlike other bacterial infections, burden of IpD continues to pose a problem worldwide by its varied epidemiological pattern, changing cellular and virulence characters and complex detection methods. World Health Organization in 2008 estimated high burden of pneumonia in Asia with most cases in India (43 million), China (21 million) and pakistan (10 million), and additional high numbers in Bangladesh and Indonesia 3 . An ideal pneumococcal vaccine which is a preventable cause of morbidity and mortality in children and high risk adults, has eluded immunization programmes. prato et al 4 has highlighted a changing scenario of the disease since the introduction of 23 valent polysaccharide vaccine. Studies on pneumococcal disease and its epidemiology are compounded by problems associated with establishing an aetiological diagnosis to determine serotype prevalence. Although several single site and a few multi site reports have been published, these have not been collated to get a nationwide comprehensive data in India.
The article by Balaji et al 5 in this issue is a report of a single centre with 114 Streptococcus pneumoniae isolates from IpD, over a period of six years (with an average of 19 per year). The magnitude of projected pneumococcal disease burden and serotype prevalence in a geographic area is not reflected by laboratory data, and therefore, it cannot be extrapolated to reflect the actual situation. One of the major challenges to serotype prevalence studies in India has been the meager laboratory data generated by a few centers only. This is understandable due to the complex laboratory procedures to isolate and serotype the organism. The authors have shown a 64 and 74.6 per cent coverage of pneumococcal conjugate vaccine-10 (pCV-10) and pCV-13 serotypes, respectively in contrast to only 48.2 per cent coverage of pCV-7. This has already been well documented in the West 6,7 , hence it is not surprising that the same should be observed in Indian children. An earlier multicentric study (IBIS) from the same centre had shown serotype prevalence in children less than five years from several hospitals across India, representing a wider geographic distribution 1 . It is to be noted that serotypes reported in the IBIS study 1 and 25.4 per cent of the isolates from the present study were nonvaccine serotypes. The implications of the non-vaccine serotypes in the prevention of IpD remain a challenge. Despite its small numbers, a positive outcome of the present study is the data on serotypes detected over a period of time indicating a wide range involved in invasive disease. predominance of some serotypes in any particular year has not been commented upon, possibly due to small numbers isolated per year.
A potential source of non-vaccine serotypes in the nasopharynx must be considered in the preventive strategy for IpD. Changing serotype pattern has been described in nasopharyngeal colonization studies which are presumed to be prelude to invasive infections 8 . There are several reports from India on serotype prevalence in nasopharyngeal colonizers in children ranging between 6.5 to 24 per cent, from the first six months of life to 10 yr of age 9, 10 . . These studies have shown substantial nonvaccine serotypes among the colonizers. Knowledge of drug resistance among the colonizers is also important to monitor circulating resistant serotypes.
Balaji et al 5 have reported decreased susceptibility to penicillin and cefotaxime among the non-vaccine serotypes. With macrolides, azithromycin and clarithromycin being widely used in respiratory tract infections, it would have been prudent to test these also. Erythromycin resistance along with high level of co-trimoxazole (which is no longer used in respiratory infections) has also been documented in other studies from India 13, 14 . unlike in some European countries 15 antibiotic resistance in pneumococci has not posed a challenge in India, except extremely high level of resistance to co-trimoxazole. With high disease burden and mortality in children due to IpD, it is not out of place to monitor for emergence of multidrug resistant strains. The easiest way to do so is to survey nasopharyngeal colonization in healthy children in the community 14,16. Reports of unique mechanisms of resistance in pneumococci have been emerging in literature from the West 17 . A close watch on antibiotic resistance of S. pneumoniae among nasopharyngeal colonizers in hospitalized children would help monitor the changing pattern under antibiotic pressure in the hospital. Millennium Development Goal 4 to reduce mortality in children less than five year old between 1990 to 2015 has moved forward in some countries by introducing vaccines with expanded serotype coverage. PCV-13 has achieved significant success in this endeavour. Further broadening the scope by including prevalent serotypes needs to be explored as well 4 . There is a need for research on non-serotype based, or novel conjugate vaccines with conserved pneumococcal protein antigens, to overcome the problems associated with existing polysaccharide vaccines. Meanwhile, serotype prevalence in invasive diseases must continue to be documented to monitor occurrence of nonvaccine serotypes and serotype switching among existing strains responsible for invasive pneumococcal disease. Documentation of serotype prevalence across the country, including high disease burden States and vulnerable child population, is necessary to guide policy makers towards introducing an effective vaccine and researchers to explore newer possibilities of novel vaccine production.
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